Literature DB >> 10087696

Case study: carbamazepine treatment of juvenile-onset bipolar disorder.

J L Woolston1.   

Abstract

The literature devoted to juvenile-onset bipolar disorder has rapidly expanded in the past 5 years with an emphasis on new concepts of prevalence and comorbid conditions. In the process of enlarging the knowledge base about the phenomenology of juvenile-onset bipolar disorder, this new literature has generated considerable controversy but has provided little information about pharmacotherapy. In the following case series, carbamazepine appeared to be a safe and effective treatment for juvenile-onset bipolar disorder. Controlled studies are necessary before any definitive conclusions can be reached about the efficacy of carbamazepine in the treatment of this form of bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087696     DOI: 10.1097/00004583-199903000-00022

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  5 in total

Review 1.  Bipolar disorder in youth.

Authors:  G A Carlson; S E Meyer
Journal:  Curr Psychiatry Rep       Date:  2000-04       Impact factor: 5.285

Review 2.  Management options for bipolar disorder in children and adolescents.

Authors:  Arman Danielyan; Robert A Kowatch
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 3.  Psychopharmacology of pediatric bipolar disorder: a review.

Authors:  Sylvester Smarty; Robert L Findling
Journal:  Psychopharmacology (Berl)       Date:  2006-11-09       Impact factor: 4.530

Review 4.  Treatment of mania in children and adolescents.

Authors:  Roomana Sheikh; Joon Kang; Ronald Weller; Elizabeth B Weller
Journal:  Curr Psychiatry Rep       Date:  2005-04       Impact factor: 8.081

5.  The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode.

Authors:  Robert L Findling; Lawrence D Ginsberg
Journal:  Neuropsychiatr Dis Treat       Date:  2014-08-27       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.